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[120_td$diff]a b s t r a c t
Intracranial aneurysms remain important clinical concern. There is relatively low risk of
rupture of symptomless aneurysms incidentally found in MRA or CTA performed due to
other indications. Not all of the intracranial aneurysms should or can be treated with
neurosurgery intervention or endovascular embolization. Clinical strategy for small, symp-
tomless, unruptured aneurysms is still questionable. Mechanisms underlying aneurysms
formation, progression and rupture are poorly understood. Inﬂammation is one of the
factors suspected to participate in these processes. Therefore the aim of this manuscript
is to present current state of knowledge about the role of inﬂammation in the formation and
progression of intracranial aneurysms and in their rupture process. Current knowledge
about possible pharmacological treatment of intracranial aneurysms will also be presented.
Macrophages inﬁltration seems to participate in the formation of intracranial aneurysms.
Inhibition of signals sent by macrophages may prevent the aneurysms formation. Inﬂam-
mation present in the wall of the aneurysm seems to be also related to the aneurysm's
rupture risk. However it does not seem to be the only cause of the degeneration, but it can be
a possible target of drug therapy. Some preliminary studies in humans indicate the potential
role of aspirin as a factor that decrease the level of inﬂammation and lower the risk of
rupture of intracranial aneurysms. However further research including a greater number of
subjects and a prospective randomized design are necessary to assess the role of aspirin in
preventing strategy for small, symptomless, unruptured intracranial aneurysms.
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its high prevalence in general population. According to
American Heart Association Statistics Committee and Stroke
Statistics Subcommittee [1] in every 1 000 000 adults of mean
age of 50 years about 32 000 have intracranial aneurysm. Every
year about 80 of them rupture causing subarachnoid hemor-
rhage that can be the cause of death of about 50% of patients.
About 1/3 of patients who survive will likely suffer from a
major neurological deﬁcits. Only neurosurgery intervention or
endovascular embolization is medical treatment strategy to
prevent rupture or to treat ruptured aneurysms. Both
procedures are not fully safe for patients and are associated
with the risk of complications, including death. Up to now
there is no recognized pharmacological strategy for aneur-
ysms treatment.
The risk of rupture of symptomless aneurysms, whichwere
incidentally found in MRA or CTA performed due to other
indications, is relatively low [2]. There is no deﬁnite method
that can predict this risk, as it is related to gender, age, size of
aneurysms, its location and irregular shape, growth time,
coexistence of other vascular lesions, family history of SAH
and prior SAH. Smoking, excessive alcohol consumption and
hypertension are the only modiﬁable risk factors [2]. In
American Heart Association/American Stroke Association
2015'Guidelines [2] there is no indication which aneurysm
size should be treated. Also in European Stroke Association
2013'Guidelines lacks such informations [3].
Taking above into account, not all of the intracranial
aneurysms should or can be treated by surgery or endovas-
cular embolization. One of the obstacles can be the lack of
patients consent or technical problems including atheroscle-
rosis in blood vessels, location of aneurysms, making surgical
or endovascular access difﬁcult or even impossible. This cause
a question about the clinical strategy for small aneurysms, not
included to the treatment. In these cases only regular MRA or
CTA examinations are recommended [2]. However there is a
lack of optimal time interval for such check-ups [2]. Another
problem is the anxiety associated with potential rupture.
Patients knowing about intracranial aneurysm in their heads
ask for the treatment. Argumentation that the risk of rupture is
low or lower that the risk associated with neurosurgery
intervention or endovascular embolization can be difﬁcult to
accept by some patients. Recent study by Yamashiro et al. [4]
showed that preoperative and postoperative quality of life of
patients with intracranial aneurysms is signiﬁcantly limited.
Potential pharmacological therapy in above cases seems to be
a reasonable solution.
Mechanisms regulating aneurysms formation, progression
and rupture are poorly understood. Inﬂammation is one of the
factors suspected to participate in these processes. Detailed
analysis of particles taking part in this state seems to lead to
identiﬁcation of therapeutic targets and creation pharmaco-
logical strategy which should inhibit the ruptures. Therefore
the aim of this manuscript is to present current state of
knowledge about the role of inﬂammation in the formation
andprogression of intracranial aneurysms and in their ruptureprocess. Also current knowledge about possible pharmacolog-
ical treatment of intracranial aneurysms will be presented.
2. Formation of intracranial aneurysmsInmost of human intracranial aneurysms it is impossible to say
whenandhowaneurysmoccurred. That'sway all of the studies
investigating aneurysms formations are based on animals. In
one of the ﬁrst studies by Kanematsu et al. [5] mice aneurysms
were induced using a combination of single injections of
elastase into the cerebrospinal ﬂuid and angiotensin II induced
hypertension. Next in the half of mice the reduction in the
number of macrophages was induced using clodronate lipo-
some. In the groupwithout blockedmacrophage the occurrence
of aneurysms was 6 out of 10; in the group with blocked
macrophage – 1 out of 10, what suggest that reduction in the
number of macrophages inhibits the formation of aneurysms.
In the same study [5] also reduced incidence of aneurysms in
mice lackingmonocyte chemotactic protein-1 (MCP-1),which is
critical chemotactic factor for proper macrophage function,
compared with the incidence of aneurysms in wild type mice,
were observed. Secretion of proteasesdestroying stromal tissue
(matrix), triggering oxidative stress and secretion of inﬂamma-
tory cytokines can link macrophages with the process of
aneurysms formation. What is more, Aoki et al. [6], based on
mice and rats with induced aneurysms studies, suggested that
induction of macrophage activity is based on cyclooxygenase 2
(COX-2) pathway activation and prostaglandin E (PGE2) via
prostaglandin E receptor (EP2) through an amplifying loop and
activationofnuclear factor-kB (NF-kB) in theendotheliumof the
cerebral arteries. It was also suggested in latter study be Aoki
et al. [7] that blocking tumor necrosis factor a receptor (TNFaR1)
forTNFreducedthe formationofaneurysms.These resultswere
conﬁrmed by other authors [8]. In the study by Nuki et al. [9]
metalloproteinase-9 (MMP-9) knockout mice, but not MMP-2
knockout mice, had a reduced incidence of intracranial
aneurysms. Metalloproteinases, produced mainly by macro-
phages, are thought todestroy arterialwall extracellularmatrix.
The role of the most important inﬂammation pathways in
the formation, progression and rupture of intracranial
aneurysms is illustrated in Scheme 1.
Later studies focused on pharmacological agents, which
can inhibit above described processes. In the study by Nuki
et al. [9] doxycycline, a broad-spectrumMMP inhibitor, reduced
the incidence of aneurysm to 10%. Among others, treatment
with simvastatin, pitavastatin, pravastatin, nifedipine, olme-
sartan, ibudilast and erythropoietin (EPO) [10–15] suppressed
the development of intracranial aneurysms in different
mechanisms. All above studies were also based on animals,
however the drugs used in them should be a candidate for
medical treatment strategy of intracranial aneurysms in
humans. Moreover, COX-2 inhibitors like aspirin or indometh-
acin [16] should be taken into account.
Summarizing, the inﬂammation seems to participate in the
formation of intracranial aneurysms. Pharmacological inhibi-
tion of macrophage inﬁltration and signaling (via the COX-2 or
NF-kB or TNFa pathways inhibition)may inhibit the formation
of aneurysms.
[(Scheme_1)TD$FIG]
Scheme 1 – The role of the most important inflammation pathways in the formation, progression and rupture of intracranial
aneurysms.
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intracranial aneurysms were also studied before. However,
most of the above cited authors did not distinguish clearly
between aneurysm formation and progression. What is more,
below-described studies on rupture of intracranial aneurysms
involved data about intracranial aneurysms wall destruction,
so that progression process. Studies on progression or growth
of aneurysms in general seems to need longer follow-ups so
that seems to be more difﬁcult to design.
Starke et al. has shown that inhibition of TNFa by
3,60dithiothalidomide (DTH) reduce progression of intracranial
aneurysms in rats [8]. It was also shown in rats that
simvastatin suppresses intracranial aneurysms progression.
Statins seem to inhibit the expression of several matrix
metalloproteinases, including MMP-2 and MMP-9 involved in
inﬂammation [10]. Furthermore, the similar suppressing effect
was observed in the study with pitavastatin. In this case
reduction in progression of intracranial aneurysms were
explained by inhibition of NF-kB by pitavastatin [11]. Also
nifedipine through inhibition of NF-kB suppressed intracranial
aneurysms progression in the study by Aoki et al. [12]. Further
studies tried to focus on destruction and remodeling of
aneurysm wall. Marbacher et al. [17] induced in rats 24
saccular aneurysms of the abdominal aorta – in half of them
number of mural cells were reduced. Aneurysms with the
reduced number of mural cells were growing and 50% of
growing aneurysms ruptured in comparison to not growing. As
concluded, the loss of mural cells causes an increase in the
size of aneurysm and its rupture. This observations were
conﬁrmed by further study in which a transplantation ofsmoothmuscle cells into the luminal thrombus of intracranial
aneurysms in rats reduced their destruction resulting in lower
recurrence and lower growth of aneurysms [18]. On the other
hand, there is no direct evidence that the complement
activation affects directly smooth muscles cells [19] and there
is no direct evidence on apoptosis induction by inﬂammatory
cells (activation of Caspase 8) in the wall of aneurysms in
humans. This indicates a potential role of other factors in the
activation of apoptosis process. In thisﬁeld, the role of Caspase
9 and oxidative stress response is suspected [20]. Also
hemooxygenaze-1, secreted by certain inﬂammatory cells,
accompanies the destruction of the walls of aneurysms and
ruptures [20]. Recently Ollikainen et al. [21,22] have indicated
the presence of mast cells and lipid accumulation in the
aneurysms wall and its contribution to remodeling and
destruction of this wall.
Another problem related to the progression of intracranial
aneurysms is their morphology which seems to be linked to
hemodynamic factors and inﬂammation. Irregular shape,
particularly presence of daughter sac, seems to be related to
higher risk of rupture. In the recent study by Abboud et al. [23]
risk of rupture increased from single sac with regular margin,
through aneurysms with irregular margin and with daughter
sac, and was the highest in multilobulated intracranial
aneurysm. Formation of daughter sac in intracranial aneur-
ysms seems to be related to hemodynamic factors causing
local elevation of pressure at the site of aneurysms without
surrounding structure, which may cancel perpendicular wall
tension [24]. However, it seems that there are no studies
investigating the role of inﬂammation factors on the forma-
tion of daughter sac in intracranial aneurysms.
In spite of the small amount of studies focusing only on
progression of intracranial aneurysms all cited studies indi-
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process. Pharmacological inhibition ofmacrophage inﬁltration
and signaling (via the COX-2 or NF-kB or TNFa pathways
inhibition) may inhibit also the progression of intracranial
aneurysms.
4. Rupture of intracranial aneurysmsIt is difﬁcult to predict which aneurysmwill rupture and cause
hemorrhages. It is suggested that the risk of rupture of
intracranial aneurysms is related among other to gender, size
of the aneurysm, its location and irregular shape, coexistence
of other vascular lesions, smoking and hypertension [2,25–28].
However this does not exclude that other factors especially on
biochemical level take part in this process. Frösen et al. [29] in
histological examination of the material obtained during
neurosurgical clipping of human 24 unruptured and 42
ruptured intracranial aneurysms found an increased inﬁltra-
tion of macrophages and proliferation of smooth muscle cells
in ruptured aneurysms. In addition, in ruptured aneurysms
M1/M2 subsets ofmacrophages balancewas lost in favor of M1
proinﬂammatory cells [30]. Level of metalloproteinases,
produced by macrophages, seems to be higher in ruptured
than in unruptured aneurysms in humans [31]. In histological
examination of the material obtained during neurosurgical
clipping of human intracranial aneurysms Tulamo et al. [19]
found that in addition to the macrophages inﬁltration, an
activation of complement (humoral response) in ruptured
aneurysms is present. In the histological examination by
Gounis et al. [32] of thematerial obtained during the clipping of
20 unruptured and 3 ruptured human intracranial aneurysms,
all ruptured aneurysms had increased myeloperoxidase
activity. In another study a 2.7-fold higher concentration of
myeloperoxidase was found in blood drawn directly from the
lumen of intracranial aneurysms in comparison to peripheral
blood [33]. It can be concluded that myeloperoxidase, secreted
mainly by neutrophils and macrophages, results in oxidative
stress and is accompanied by an increased risk of aneurysms
rupture.
As discussed, many studies conﬁrmed that inﬂammation
accompanies the rupture of aneurysms in humans. There are
other factors like loss of smooth muscle cells that seems to
contribute to destruction of aneurysms wall and to the
ruptures of aneurysms, as well. Some inﬂammatory cells
may cause oxidative stress and this in turn may affect the
ruptures of aneurysms.
It is unknown how well-known risk factors like smoking or
hypertension [2,25–28] can affect or trigger the inﬂammation
and cause rupture. Recent study onhumansbyCebral et al. [34]
indicated that ﬂow conditions in saccular intracranial aneur-
ysms, assessed on the basis of patient-speciﬁc computational
models of hemodynamic (computational ﬂuid dynamics –
CFD) created from preoperative CT angiographies were
associated with wall remodeling. More diffuse inﬂow was
associated with degenerated and decellularized saccular
aneurysm walls, assessed in histological examinations of
material obtained in neurosurgical clipping. Also low ﬂow
conditions were associated with wall changes. These observa-
tions suggest that endothelial injury may be a mechanism bywhich ﬂow induces the inﬂammation in the intracranial
aneurysms wall. Also Jamous et al. [35,36] indicated that
endothelial cell injury is the earliest change in aneurysmwall.
However there are many controversy about the role of
hemodynamic factors on the rupture risk of intracranial
aneurysms [34,37–39]. In the last review and meta analysis
study Can et al. [37] showed that increase in wall shear stress
(WSS), deﬁned as tangiental frictional force exerted by ﬂowing
blood on the arterial endothelium, proportional to the blood
viscosity and velocity gradients [38], may contribute to
aneurysms formation, whereas low WSS seems to be
associated with raptured aneurysms. It can be explained that
high WSS implicates wall remodeling and potential destruc-
tion via endothelial injury. Low WSS, on the other hands, can
cause localized stasis of blood ﬂow near the aneurysms wall
causing endothelial dysfunction and elevation of proinﬂam-
matory factors [37,39]. Interpretation of the results of studies
on hemodynamic factors remains difﬁcult, while among
others except WSS other indexes have been proposed and
used [37], there are differences induced by diverse conﬁgura-
tions and geometries of vessels of the anterior and posterior
circulations [40]. Furthermore, some studies investigating
hemodynamics factors were performed for sidewall aneur-
ysms, while others – for bifurcation aneurysms [37].
There is a group of other factors involved in rupture
process. It cannot be excluded that they modify above
described observations. As proved by Pena Silva et al. [41]
angiotensin (1–7) via Mas receptor reduces the formation of
intracranial aneurysms and reduces their rupture probability.
Shimada et al. [42] indicated also the protective role of
angiotensin (1–7) however via angiotensin II type 2 receptor
(ATR2) pathway. What is more, angiotensin (1–7) in this study
reduced the expression of TNFa. In another study Shimada
et al. [43] showed that activation of PPAR-y (Peroxisome
Proliferator-Activated Receptor-y) on macrophages by piogli-
tazone (PGZ) reduced macrophages inﬁltration and level of
inﬂammatory cytokines (interleukin-1 and interleukin-6)
resulting in decreasing aneurysm rupture risk. Hasan et al.
[44] conﬁrmed this results, indicating the important role of
smooth muscle cell PPAR-y. Pena Silva et al. [45] suggests that
hepatocyte growth factor (HGF) reduces inﬂammation and
prevents rupture of intracranial aneurysms. In another study
by Tada et al. [46,47] estrogen (via b receptor for estrogen)
seems to prevent the rupture of intracranial aneurysms. This
seems to stay in line with clinical observations that the
prevalence of hemorrhage caused by intracranial aneurysms
rupture in postmenopausal women is higher than in premen-
opausal women [48]. Also hormonal replacement therapy
(HRT) including estrogens seems to decrease rupture risk in
postmenopausal women [49]. All above studies were based on
animals.
Furthermore, comparison of gene expression by Kurki et al.
[50] of 8 ruptured and 11 unruptured human aneurysms
showed that the accumulation of lipids was strongly linked
with rupture. Additionally, this seems to be linked to the fact
that lipid accumulation in the wall of aneurysms is associated
with loss of wall cells [51] and is associated with an activation
of the complement system [52]. On the other hand, Pyysalo
et al. [53,54] showed the presence of the bacterial DNA speciﬁc
to themouth in the intracranial aneurysms. This results raised
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and rupture of intracranial aneurysms.
Summarizing, inﬂammation in the wall of the aneurysm
seems to be accompanied by destruction of the wall and the
risk of rupture. This suggest a potential role of inﬂammation as
a marker of rupture risk. If proper assessment tool is created,
we will be able to recognize aneurysms with high risk of
rupture and treat only them. This can be also useful in case of
SAH and multiple intracranial aneurysms, when it is impossi-
ble to say which aneurysm caused hemorrhage. Assessing the
inﬂammation state should help clinicians to indicate this
aneurysm [55,56]. Secondly, inﬂammation does not seem to be
the only cause of the destruction of the wall of the aneurysm,
but it can be a possible target of drug therapy.
5. Perspectives of possible pharmacological
treatment of intracranial aneurysmsThere are some studies focusing on the role of aspirin as a
well-known agent against inﬂammation. Except for blocking
COX-2 and microsomal prostaglandin E2 synthase 1 (mPGES-
1), aspirin was shown to inhibit MMP-2 and MMP-9 expression
[57], TNFa in smooth muscle cells [58] and to reduce NF-kB
activity [58,59].
In the study by Li et al. [60], ﬁrstly intracranial aneurysms in
rats were induced. The group was divided into aspirin-treated
and untreated control group. Then the aneurysms wall were
histologically examined. As concluded, aspirin reduced the
destruction of the wall of the aneurysm and lowered
inﬂammatory markers (reduced expression of MMP-2 and
MMP-9, reverse upregulation of NF-kB, MCP-1 and vascular cell
adhesion molecule-1 – VCAM-1).
A retrospective evaluation by Hasan et al. [61] of 271
untreated aneurysms of patients from International Study of
Unruptured Intracranial Aneurysms (ISUIA), in which patients
were divided on the basis of interview into group using aspirin
(≥3 times a week) and groups of nonusers of aspirin (‘‘less than
once o month’’ and ‘‘between once a month and twice a
week’’). In the group of patients taking aspirin (≥3 times a
week) a fewer incidents of aneurysms ruptures were observed.
Another retrospective assessment of 1797 patients with
intracerebral haemorrhages and 1340 patients with SAH by
Garcia-Rodriguez et al. [62] showed that aspirin was not
associated with the risk of intracerebral bleeding, however
chronic low-dose of aspirin (75–300 mg/day) reduced the risk
of SAH. Results of the retrospective study by Gross et al. [63] of
747 patients with brain aneurysms indicated that the risk of
SAH is lower in the group receiving aspirin compared to those
not taking it (28% vs 40%). However in this study among
patients with SAH there were no signiﬁcant difference in
presenting clinical and radiological grade, measured by Hunt-
Hess and Fisher Scales, between patients taking and not-
taking aspirin. What is more, aspirin use was not associated
with 1-year poor outcome.
Another study design was proposed by Hasan et al. [64]. In
this study 11 patients with intracranial aneurysms were
divided into two groups: 6 people – treatedwith aspirin (81 mg/
day) and 5 people – control group. Initially inﬂammation in
aneurysms wall was assessed in MR enhanced with Ferumox-ytol. After three months second MR scanning was performed
to assess the inﬂammation process. Then, surgical clipping of
aneurysms was performed and obtained material was histo-
logically examined. Both histological andMR results suggested
that aspirin reduced inﬂammation in the wall of aneurysms.
Ferumoxytol used in this study is a relatively newnanoparticle
containing iron oxide coated by carbohydrate shell. It belongs
to ultrasmall superparamagnetic iron oxide (USPIOs) and was
initially developed for threating iron deﬁciency anemia in
patients with chronic renal failure [65]. It can be used as
enhancement medium and T2*-weight gradient-echo imaging
is usually applied for evaluation of macrophage inﬁltration
within the aneurysms wall. Ferumoxytol is usually adminis-
tered intravascular about 24–72 h before MR imaging. In this
time it is absorbed by macrophages and they, as mentioned
above, accumulate in the area of inﬂammation [66–68].
Objective comparison of above described studies is difﬁcult
because of their limitations like relatively small sample size.
Presence of potential confounding variables should be also
taken into account. It should be emphasized, that most of
studies on humans had retrospective design and doses of
aspirin used in particular studies were different. However, on
the basis of all above preliminary studies in animals and
humans, it seems that small doses of aspirin can reduce the
risk of aneurysms rupture. Further research including a greater
number of subjects and prospective randomized design to
assess the role of aspirin as a potential preventing strategy for
small, symptomless, unruptured intracranial are inevitable.
It is worth to mention that some of authors indicate the
possible role of another pharmacological agents like tetracy-
cline (minocycline and doxycycline) in prevention of intracra-
nial aneurysms rupture [69]. However this study, like most of
the above, was based on mice. Also previously mentioned
statins and other medications [10–15], blocking formations of
intracranial aneurysm in animal's models, should be taken
into account as potential prevention strategy. However initial
studies with statins performed on humans gave inconclusive
results [70–72].
6. ConclusionFollowing above review of literature (however not a systematic
review) it can be concluded that inﬂammation appears to
mediate in the formation and progression of intracranial
aneurysms and seems to be related to its rupture risk. This
suggests a potential role of inﬂammation as a marker of
aneurysm's rupture risk. Furthermore, inﬂammation can be a
possible target for drug therapy. Preliminary studies on
animals and humans indicate that small doses of aspirin
can reduce the risk of aneurysms rupture. However further
research including greater number of subjects and prospective
randomized design are necessary to assess the role of aspirin
as a potential preventing strategy for small, symptomless,
unruptured intracranial aneurysms.
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